Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up.

By using stereotaxic surgical techniques, ventral mesencephalic tissues from aborted human fetuses of 8 to 10 weeks' gestational age were implanted unilaterally into the striata in two patients with advanced Parkinson's disease. The patients were treated with a cyclosporine, azathioprine, and steroid regimen to minimize the risk for graft rejection. They were examined for 6 months preoperatively and 6 months postoperatively and continued to receive the same doses of antiparkinsonian medication. There were no significant postoperative complications. No major therapeutic effect from the operation was observed. However, in the clinical tests, both patients showed small but significant increases of movement speed for repeated pronation-supination, fist clenching, and foot lifting. The rate of walking also increased in the one patient tested. For both patients, there was an initial worsening postoperatively, followed by improvement vs preoperative performance at 1 to 3 months. Both patients also showed significant improvement in the magnitude of response to a single dose of levodopa (L-dopa), but there was no increase in the duration of drug action. The motor readiness potential increased in both patients postoperatively, primarily over the operated hemisphere. Neurophysiological measurements also showed a more rapid performance of simple and complex arm and hand movements on the side contralateral to transplantation in one patient at 5 months postoperatively. Positron emission tomography demonstrated no increased uptake of 6-L-(18F)-fluorodopa in the transplanted striatum at 5 and 6 months. Taken together, these results suggest that the fetal nigral implants may have provided a modest improvement in motor function, consistent with the presence of small surviving grafts. Although our results support further scientific experimentation with transplantation in Parkinson's disease, widespread clinical trials with this procedure are probably not warranted at this time.

[1]  R. Bakay,et al.  Biochemical and Behavioral Correction of MPTP Parkinson‐like Syndrome by Fetal Cell Transplantation a , 1987, Annals of the New York Academy of Sciences.

[2]  R. Roth,et al.  Fetal dopamine neural grafts: extended reversal of methylphenyltetrahydropyridine-induced parkinsonism in monkeys. , 1988, Progress in brain research.

[3]  A. Björklund,et al.  Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis , 1987, Neuroscience.

[4]  Frances K. Graham,et al.  Memory-for-Designs Test: Revised General Manual , 1960 .

[5]  W. Freed,et al.  Restoration of dopaminergic function by grafting of fetal rat substantia nigra to the caudate nucleus: Long‐term behavioral, biochemical, and histochemical studies , 1980, Annals of neurology.

[6]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[7]  C. Marsden,et al.  Disturbance of sequential movements in patients with Parkinson's disease. , 1987, Brain : a journal of neurology.

[8]  G. Gerhardt,et al.  Intracerebral xenografts of human mesencephalic tissue into athymic rats: immunochemical and in vivo electrochemical studies. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[9]  L. Olson,et al.  Substantia nigra transplants into denervated striatum of the rat: Ultrastructure of graft and host interconnections , 1985, The Journal of comparative neurology.

[10]  Y. Agid,et al.  Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. , 1973, Nature: New biology.

[11]  R. Bakay,et al.  Preliminary report on the use of fetal tissue transplantation to correct MPTP-induced Parkinson-like syndrome in primates. , 1985, Applied neurophysiology.

[12]  C Nahmias,et al.  Cerebral Metabolism of 6–[18F]Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Primate , 1987, Journal of neurochemistry.

[13]  T Jones,et al.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[14]  G. Sedvall,et al.  Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. , 1985, Journal of neurosurgery.

[15]  L. Olson,et al.  Reinnervation of dopamine-denervated striatum by substantia nigra transplants: Immunohistochemical and electrophysiological correlates , 1985, Neuroscience.

[16]  Coons Ah Fluorescent antibody methods , 1968 .

[17]  Forno Ls,et al.  The Lewy body in Parkinson's disease. , 1987 .

[18]  G. Arbuthnott,et al.  Electrophysiological properties of single units in dopamine-rich mesencephalic transplants in rat brain , 1985, Neuroscience Letters.

[19]  M. Moal,et al.  Activation of striatal dopaminergic grafts by haloperidol , 1985, Brain Research Bulletin.

[20]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[21]  G. Rose,et al.  Monoamine release from dopamine-depleted rat caudate nucleus reinnervated by substantia nigra transplants: An in vivo electrochemical study , 1985, Brain Research.

[22]  E. Möller,et al.  No effect of blood transfusions or HLA matching on renal graft success rate in recipients treated with cyclosporine-prednisolone or cyclosporine-azathioprine-prednisolone: the Scandinavian experience. , 1988, Transplantation proceedings.

[23]  R. Duvoisin,et al.  Speculations on the etiology of Parkinson's disease. , 1984, Advances in neurology.

[24]  A. Granholm,et al.  Human fetal mesencephalic tissue grafted to dopamine-denervated striatum of athymic rats: light- and electron-microscopical histochemistry and in vivo chronoamperometric studies , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[25]  A. Bjo¨rklund,et al.  Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants , 1979, Brain Research.

[26]  E. Melamed Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. , 1986, Archives of neurology.

[27]  A. Bjo¨rklund,et al.  Transplantation of central and peripheral monoamine neurons to the adult rat brain: Techniques and conditions for survival , 1976, Brain Research.

[28]  H. Scheffé,et al.  The Analysis of Variance , 1960 .

[29]  F. Gage,et al.  In vivo measurement of spontaneous release and metabolism of dopamine from intrastriatal nigral grafts using intracerebral dialysis , 1986, Brain Research.

[30]  C. Clough,et al.  EMBRYOS AND PARKINSON'S DISEASE , 1988, The Lancet.

[31]  E. Thorsby,et al.  Antigens on Human Fibroblasts Demonstrated with HL‐A Antisera and Anti‐Human Lymphocytic Sera , 1968, Vox sanguinis.

[32]  B J Hoffer,et al.  Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. , 1979, Science.

[33]  R. Penn,et al.  The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. , 1988, Neurosurgery.

[34]  L. Olson,et al.  Human fetal substantia nigra grafted to the dopamine-denervated striatum of immunosuppressed rats: evidence for functional reinnervation , 1986, Neuroscience Letters.

[35]  J C Rothwell,et al.  The Bereitschaftspotential, L-DOPA and Parkinson's disease. , 1987, Electroencephalography and Clinical Neurophysiology.

[36]  S. Haber,et al.  Survival and growth of fetal catecholamine neurons transplanted into primate brain , 1986, Brain Research Bulletin.

[37]  S. Haber,et al.  FETAL NEURONAL GRAFTS IN MONKEYS GIVEN METHYLPHENYLTETRAHYDROPYRIDINE , 1986, The Lancet.

[38]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[39]  O. Lindvall,et al.  Transplantation in Parkinson's disease: Two cases of adrenal medullary grafts to the putamen , 1987, Annals of neurology.

[40]  P. Nunn,et al.  Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. , 1987, Science.

[41]  J. Peuler,et al.  Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. , 1977, Life sciences.

[42]  L. Molander,et al.  MEMORY DISTURBANCES AFTER ELECTROCONVULSIVE THERAPY , 1957, Acta psychiatrica et neurologica Scandinavica.

[43]  J. Powell,et al.  Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: a tyrosine hydroxylase immunocytochemical study , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[44]  F. Gage,et al.  Intracerebral grafting of neuronal cell suspensions. II. Survival and growth of nigral cells implanted in different brain sites , 1983 .

[45]  W. Freed,et al.  Normalization of spiroperidol binding in the denervated rat striatum by homologous grafts of substantia nigra. , 1983, Science.

[46]  Y. Naum,et al.  Growth of Pulmonary Alveolar Macrophages in vitro , 1973, Nature.

[47]  C. Nahmias,et al.  Central Dopaminergic Pathways in Hemiparkinsonism Examined by Positron Emission Tomography , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[48]  A. Björklund,et al.  Reinnervation of the denervated striatum by substantia nigra transplants: Functional consequences as revealed by pharmacological and sensorimotor testing , 1980, Brain Research.

[49]  J. D. Parkes,et al.  Fluctuations of disability in Parkinson's disease – clinical aspects , 1981 .

[50]  S. Hunt,et al.  Transplantation of embryonic marmoset dopaminergic neurons to the corpus striatum of marmosets rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1988, Progress in brain research.

[51]  J. Langston,et al.  1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra , 1984, Neuroscience Letters.

[52]  R. Drucker-Colín,et al.  Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. , 1988, The New England journal of medicine.

[53]  Voon Wee Yong,et al.  Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients , 1986, Neuroscience Letters.

[54]  S. Kish,et al.  Glutathione peroxidase activity in Parkinson's disease brain , 1985, Neuroscience Letters.

[55]  F. Gage,et al.  Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral suspension implants as assessed by measurements of dopamine synthesis and metabolism. , 1983, Acta physiologica Scandinavica. Supplementum.

[56]  P. A. Peterson,et al.  Genomic hybridization with class II transplantation antigen cDNA probes as a complementary technique in tissue typing. , 1984, Human immunology.

[57]  B. J. Hopper,et al.  FETAL DOPAMINE-RICH MESENCEPHALIC GRAFTS IN PARKINSON'S DISEASE , 1988, The Lancet.

[58]  A. Barbeau,et al.  Environmental and genetic factors in the etiology of Parkinson's disease. , 1987, Advances in neurology.

[59]  A. Björklund,et al.  Functional Activity of Substantia Nigra Grafts Reinnervating the Striatum: Neurotransmitter Metabolism and [14C]2‐Deoxy‐d‐glucose Autoradiography , 1982, Journal of neurochemistry.

[60]  A. Björklund,et al.  Functional reinnervation of the denervated neostriatum by nigral transplants , 1980, Peptides.

[61]  A. Bjo¨rklund,et al.  Monitoring of cell viability in suspensions of embryonic CNS tissue and its use as a criterion for intracerebral graft survival , 1985, Brain Research.